Hepatoma

Hepatoma—now more correctly called hepatocellular carcinoma (HCC)—is a primary liver cancer. That means it starts in liver cells (hepatocytes), not somewhere else. Most people who develop HCC already have long-term liver damage (for example from hepatitis B or C, heavy alcohol use, fatty liver disease, or aflatoxin exposure). Over years, scar tissue (cirrhosis) forms, and some scarred cells change in a harmful way and grow as a tumor. Small HCCs may cause no symptoms. Larger ones can cause pain under the right ribs, swelling of the belly (ascites), weight loss, jaundice (yellow eyes/skin), or sudden bleeding in the stomach or intestines. Doctors stage HCC and pick treatment based on tumor size/number, whether blood vessels are involved, whether the liver still works well, and the person’s overall health.

Hepatoma means cancer that starts in the main liver cells, called hepatocytes. Today doctors prefer the term hepatocellular carcinoma (HCC). This tumor begins inside the liver, not from another organ that later spreads to the liver. The disease often grows in livers that are already scarred by long-term damage, such as hepatitis B or C, heavy alcohol use, or fatty liver disease.

Cancer cells in HCC form nodules or masses. They grow new blood vessels and take blood supply early (in the “arterial phase”), which is a clue on scans. As they grow, they can press on nearby structures, invade blood vessels (especially the portal vein), or spread within the liver or to other parts of the body. The illness may be silent at first. Later it can cause pain in the right upper belly, weight loss, swelling from fluid (ascites), yellowing of the eyes and skin (jaundice), or confusion due to liver failure (hepatic encephalopathy).

Doctors diagnose HCC using a mix of imaging, blood tests, and sometimes biopsy. In many cases, if the liver is cirrhotic and the scan shows the classic pattern, a biopsy is not needed. Early detection matters because small tumors can sometimes be removed, ablated, or treated with curative intent. When found late, care focuses on controlling growth, keeping blood flow open, and easing symptoms.

Other names

Hepatoma is most commonly called hepatocellular carcinoma (HCC). Other phrases include primary liver cancer, malignant hepatoma, and primary hepatocellular cancer. Special variants include fibrolamellar carcinoma (a type in younger people without cirrhosis), clear-cell HCC, scirrhous HCC, steatohepatitic HCC, macro-trabecular-massive HCC, sarcomatoid HCC, and combined hepatocellular-cholangiocarcinoma (cHCC-CCA) when liver cell and bile duct features mix. In older literature you may also see hepatocarcinoma or primary hepatic cell carcinoma.

Types

HCC can be grouped in several practical ways. Each “type” below is a plain-English label with a short description.

By growth pattern in the liver

• Nodular (multinodular) HCC: Multiple small tumors scattered through the liver. Common in cirrhosis and often found on routine screening.

• Massive (solitary) HCC: One dominant, larger mass that may have smaller satellite nodules around it.

• Diffuse or infiltrative HCC: Cancer spreads widely through liver tissue without a clear edge; harder to see and treat.

By cell appearance under the microscope (histology / grade)

• Well-differentiated HCC: Cells look more like normal liver cells; tends to grow more slowly.

• Moderately differentiated HCC: Middle behavior and appearance.

• Poorly differentiated HCC: Cells look very abnormal; tends to grow and spread faster.

Special histologic variants

• Fibrolamellar carcinoma: Usually in adolescents or young adults, often without cirrhosis; dense fibrous bands in the tumor.

• Clear-cell HCC: Tumor cells look “clear” due to fat or glycogen; behavior varies.

• Scirrhous HCC: Lots of fibrous tissue; can mimic other tumors on imaging.

• Steatohepatitic HCC: Tumor shows fat, inflammation, and “ballooned” cells, similar to fatty liver injury.

• Macro-trabecular-massive HCC: Thick plates (“trabeculae”) of tumor cells; often more aggressive.

• Sarcomatoid HCC: Spindle-shaped cells; rare and aggressive.

• Combined HCC-cholangiocarcinoma (cHCC-CCA): Mixed liver-cell and bile-duct features; needs special diagnosis and care.

By background liver

• HCC in cirrhosis: Most common; arises on scars from long-term liver injury.

• HCC without cirrhosis: Seen with hepatitis B, fibrolamellar carcinoma, or metabolic risks where cirrhosis may not be present.

Causes

Below are 20 well-established causes and risk factors that raise the chance of hepatoma/HCC. Each item is short and plain.

1. Chronic hepatitis B virus (HBV): HBV DNA can damage cell genes directly and also cause long-term inflammation, leading to cancer even without cirrhosis.

2. Chronic hepatitis C virus (HCV): Ongoing liver inflammation and scarring from HCV drive cirrhosis, which strongly predisposes to HCC.

3. Cirrhosis of any cause: Scarred liver tissue promotes abnormal regeneration and genetic errors that can become cancer.

4. Alcohol-related liver disease: Heavy, long-term drinking causes fatty change, hepatitis, and cirrhosis, all of which raise HCC risk.

5. Non-alcoholic fatty liver disease (NAFLD) and NASH: Fatty liver, especially NASH, can progress to cirrhosis and HCC; risk rises with diabetes and obesity.

6. Aflatoxin B1 exposure: Toxins from Aspergillus molds (often in poorly stored grains/nuts) cause DNA mutations, especially when combined with HBV.

7. Hereditary hemochromatosis: Iron overload injures hepatocytes and leads to cirrhosis and cancer.

8. Alpha-1 antitrypsin deficiency: Misfolded protein builds up in liver cells and causes chronic injury and cirrhosis.

9. Wilson disease: Copper overload triggers inflammation and scarring; untreated disease raises HCC risk.

10. Autoimmune hepatitis: Immune attack on the liver causes chronic damage and cirrhosis over time.

11. Primary biliary cholangitis (PBC): Chronic bile duct injury leads to cirrhosis; HCC risk rises, especially in men or advanced disease.

12. Diabetes mellitus (type 2): Insulin resistance and metabolic inflammation increase HCC risk, often via NASH.

13. Obesity and metabolic syndrome: These drive fatty liver and NASH, which raise HCC risk independent of alcohol.

14. Smoking: Tobacco carcinogens increase many cancer risks, including HCC.

15. Androgenic anabolic steroids: Long-term use is linked to liver tumors; some benign adenomas can transform to HCC.

16. Oral or exogenous estrogens (high dose/long term): Mainly linked to adenomas; rare malignant change can lead to HCC.

17. Arsenic exposure in drinking water: Chronic exposure raises liver cancer risk.

18. Family history or genetic susceptibility: First-degree relatives with HCC suggest shared viral, metabolic, or genetic risks.

19. HIV co-infection with HBV or HCV: Faster fibrosis progression raises HCC risk.

20. Prior liver adenoma or dysplastic nodules in cirrhosis: Pre-cancerous lesions can evolve into HCC under ongoing injury.

Symptoms

Symptoms vary. Many people feel fine early on. Below are 15 common symptoms or signs explained simply.

1. Right upper abdominal pain or fullness: A growing liver mass stretches the liver capsule and causes discomfort.

2. Unintentional weight loss: Cancer uses energy and reduces appetite.

3. Poor appetite and early fullness: Pressure on the stomach and systemic illness lower food intake.

4. Nausea or occasional vomiting: From liver swelling, medications, or metabolic changes.

5. Fatigue and weakness: Due to cancer-related inflammation, anemia, or liver failure.

6. Fever (low-grade): Tumor-related inflammation can cause intermittent fever.

7. Jaundice (yellow eyes/skin): Blocked bile flow or failing liver cells raise bilirubin.

8. Dark urine and pale stools: From high bilirubin not reaching the gut normally.

9. Itching (pruritus): Bile salts in the skin cause itch in cholestasis.

10. Abdominal swelling (ascites): Fluid builds up when portal pressure rises and albumin falls.

11. Leg swelling (edema): Low albumin and high venous pressure cause fluid in the legs.

12. A lump in the right upper abdomen: A large liver edge or mass may be felt.

13. Shoulder or back pain: Irritation of the diaphragm or referred pain from the liver.

14. Easy bruising or bleeding: Poor clotting due to decreased liver protein production.

15. Confusion or sleep changes (encephalopathy): Toxins like ammonia build up when the liver cannot clear them.

Diagnostic tests

Doctors do not rely on one test. They combine your story, exam, blood work, and imaging. In many people with cirrhosis, a typical enhancement pattern on multiphase imaging is enough for diagnosis without biopsy. Below are tests, grouped by category, with what each does and why it matters.

A) Physical exam

1) Abdominal inspection and general look
The doctor looks for weight loss, muscle wasting, and a swollen belly. They also check for yellow eyes/skin and scratch marks from itching. These clues suggest chronic liver disease and possible tumor-related changes.

2) Palpation of the liver edge
The doctor gently feels under the right rib cage for an enlarged, firm, or nodular liver. A hard, irregular edge can suggest a mass. Tenderness may indicate stretching of the capsule or inflammation.

3) Assessment for stigmata of chronic liver disease
Spider veins on the skin, red palms, gynecomastia, and testicular atrophy point to long-standing liver injury, which raises HCC risk and affects treatment choices.

4) Check for jaundice and mental status
Yellowing, a sweet/musty breath odor (fetor hepaticus), and confusion or asterixis (flapping tremor) reflect poor liver function—important for staging and safety of therapy.

B) Manual bedside maneuvers

5) Shifting dullness for ascites
The doctor percusses the abdomen while you change position. A shift in the “dull” sound suggests free fluid. Ascites is common when portal pressure is high due to cirrhosis or tumor invasion.

6) Fluid wave (fluid thrill) test
With hands placed on the abdomen, a tap on one side may transmit a wave felt on the other, suggesting significant fluid. This supports the presence of portal hypertension and advanced disease.

7) Scratch test for liver size
A stethoscope on the upper abdomen and gentle skin scratching help outline the upper liver border by sound changes. It can roughly estimate liver size when palpation is difficult.

8) Palpation/percussion for splenomegaly
An enlarged spleen supports portal hypertension. This matters because splenomegaly and low platelets can limit biopsy or surgery options.

C) Lab and pathological tests

9) Liver function panel (AST, ALT, ALP, GGT, bilirubin, albumin)
These numbers show inflammation (AST/ALT), cholestasis (ALP/GGT), bile buildup (bilirubin), and protein-making ability (albumin). They help separate active hepatitis, bile blockage, and liver failure.

10) Alpha-fetoprotein (AFP)
AFP is a tumor marker made by some HCCs. A high or rising AFP supports the diagnosis, but not all tumors make AFP. Doctors use it with imaging and over time for monitoring.

11) Des-gamma-carboxy prothrombin (DCP, also called PIVKA-II)
This abnormal clotting protein rises in many HCCs and can add accuracy when AFP is normal or borderline. It is helpful for surveillance and treatment follow-up.

12) Viral hepatitis tests (HBsAg, HBV DNA; anti-HCV, HCV RNA)
These show ongoing hepatitis B or C. Knowing viral status guides treatment, predicts risk of new tumors, and can change therapy choices.

13) Coagulation and blood counts (INR, platelets, CBC)
INR shows clotting capacity made by the liver. Platelets are often low in portal hypertension. Anemia or infection can change treatment plans and anesthesia risk.

14) Liver biopsy with histopathology and immunohistochemistry
When imaging is not classic or the liver is not cirrhotic, a needle sample may be taken. Pathologists look for liver-cell markers (such as HepPar-1, Arginase-1, Glypican-3) and rule out other cancers. Biopsy also allows molecular studies when needed. It is avoided if imaging is diagnostic or bleeding risk is high.

D) Electrodiagnostic tests

Note: There is no specific “electrodiagnostic” test that diagnoses HCC. These tests help assess complications and fitness for therapy.

15) Electrocardiogram (ECG)
An ECG checks heart rhythm and prior heart injury. It is important before major surgery, embolization, or systemic therapy that may stress the heart.

16) Electroencephalogram (EEG) in encephalopathy
If there is confusion and the cause is unclear, EEG can show generalized slowing that supports hepatic encephalopathy and helps rule out seizures. This affects safety of procedures and medication dosing.

E) Imaging tests

17) Abdominal ultrasound with Doppler
This is often the first test. It screens the liver for nodules and checks blood flow in the portal and hepatic veins. It is safe, available, and repeatable. Doppler can show tumor invasion into vessels.

18) Multiphase contrast-enhanced CT
A CT scan taken in arterial, portal venous, and delayed phases is key. HCC often “lights up” early (arterial enhancement) and then becomes less dense later (washout). This pattern in a cirrhotic liver can be diagnostic without biopsy.

19) MRI of the liver with dynamic contrast (± hepatobiliary agents) and LI-RADS
MRI offers great soft-tissue detail. Special contrast and sequences show fat, iron, and microscopic features. Radiologists use LI-RADS categories to grade how likely a lesion is HCC. Typical arterial enhancement and portal/delayed washout in the right setting can confirm HCC.

20) Contrast-enhanced ultrasound (CEUS)
Microbubble contrast during ultrasound shows real-time blood flow. Arterial “fill-in” with later washout supports HCC. CEUS helps when CT/MRI contrast is unsafe and is useful for guiding ablation.

Non-pharmacological treatments

Physiotherapy

1. Energy-conserving activity pacing
   Description (≈150 words): Fatigue is one of the hardest symptoms in HCC—caused by cancer, poor sleep, anemia, low calories, and treatments. Activity pacing teaches you to spread tasks through the day, break big jobs into short sets, and rest before you crash. A therapist helps you set a daily rhythm: wake time, meals, light movement, short rests, and a firm bedtime. You learn to use checklists, timers, and sit-to-stand work options. You also learn “priority stacking” so the most important activities happen when your energy is best. Over one to two weeks, you record what drains energy and what restores it (for example a 10-minute walk can lift energy later in the day). Purpose: reduce fatigue while keeping you moving. Mechanism: balances energy output with recovery and improves mitochondrial efficiency over time. Benefits: more stable energy, fewer “crash” days, better mood, better participation in treatment.

2. Diaphragmatic breathing for ascites discomfort
   Description: Gentle belly breathing relaxes tight abdominal muscles, improves diaphragmatic movement pressed by ascites, and reduces breathlessness. Practice 5–10 minutes, 2–3 times daily, lying on your back with knees bent or seated supported. Purpose: ease tension and improve comfort. Mechanism: increases parasympathetic tone, reduces accessory muscle overuse, and slightly improves ventilation. Benefits: less breathlessness, better sleep onset, calmer body.

3. Low-impact aerobic walking plan
   Description: Start with 5–10 minutes of slow walking, most days, and build to 20–30 minutes if approved by your doctor. Purpose: fight fatigue and deconditioning. Mechanism: improves oxygen use, muscle oxidative capacity. Benefits: more stamina, better appetite and mood.

4. Light resistance training (bands/bodyweight)
   Description: 2–3 sessions/week, 6–8 gentle exercises (for example sit-to-stand, wall push-ups, band rows). Purpose: maintain muscle in cancer-related weight loss. Mechanism: stimulates muscle protein synthesis. Benefits: strength for daily tasks, safer mobility.

5. Balance and fall-prevention drills
   Description: Heel-to-toe walking near a counter, single-leg stands with support, and home hazard removal. Purpose: prevent falls when weak or dizzy. Mechanism: trains proprioception and ankle/hip strategies. Benefits: fewer injuries, more confidence.

6. Posture and thoracic mobility work
   Description: Gentle chest opening, shoulder blade squeezes, and thoracic rotations to limit protective hunching from pain. Purpose: reduce back/neck strain. Mechanism: improves joint mobility and muscle balance. Benefits: easier breathing, less ache.

7. Gentle abdominal wall support
   Description: Teach safe ways to cough, roll, and stand with a pillow or binder (if prescribed) to support an enlarged belly. Purpose: lower strain and pain. Mechanism: reduces shear on abdominal wall. Benefits: more comfortable movement.

8. Edema management and leg elevation
   Description: Daily ankle pumps, calf stretches, and leg elevation 20–30 minutes. Purpose: reduce leg swelling when albumin is low. Mechanism: enhances venous/lymphatic return. Benefits: less heaviness and cramping.

9. Breath-paced stretching sequence
   Description: 10–15 minutes of slow hamstring, hip flexor, chest stretch with timed exhale. Purpose: down-regulate tension. Mechanism: increases vagal tone. Benefits: better sleep and pain control.

10. Inspiratory muscle training (if cleared)
    Description: Simple handheld trainer, low resistance, 5–10 minutes/day. Purpose: improve breath endurance. Mechanism: strengthens diaphragm. Benefits: less breathlessness on exertion.

11. Safe core re-activation
    Description: Very gentle pelvic tilts, knee fall-outs, and abdominal bracing without Valsalva. Purpose: support spine and transfers. Mechanism: coordinates deep core. Benefits: easier sitting and walking.

12. Sit-stand micro-breaks
    Description: Stand and move 2–3 minutes every 30–45 minutes. Purpose: reduce stiffness and clot risk. Mechanism: increases lower-limb muscle pump. Benefits: better circulation and focus.

13. Neuropathy-aware foot care exercises
    Description: If you receive certain drugs, check feet daily, do ankle circles, towel scrunches. Purpose: maintain foot function. Mechanism: keeps small muscles active. Benefits: steadier gait, fewer sores.

14. Heat/cold for localized pain (as advised)
    Description: Short, safe sessions with cloth barrier; avoid on numb skin or over the liver area without clearance. Purpose: symptom relief. Mechanism: modulates nerve signaling. Benefits: less ache, better function.

15. Pulmonary hygiene (if fluid build-up)
    Description: Incentive spirometer or deep breathing with huffs to clear secretions when bed-bound. Purpose: prevent infections. Mechanism: expands alveoli. Benefits: fewer chest infections.

Mind-Body & Educational Therapies

16. Cognitive-behavioral therapy for cancer fatigue
    Description: Brief weekly sessions to challenge unhelpful thoughts (“I must do everything”), set gentle goals, and improve sleep routines. Purpose: lower fatigue and anxiety. Mechanism: cognitive reframing and behavioral activation. Benefits: steadier energy, better mood.

17. Mindfulness meditation (10 minutes/day)
    Description: Focus on breath or body scan. Purpose: reduce stress, pain perception. Mechanism: settles limbic reactivity. Benefits: calmer mind, improved sleep.

18. Guided imagery for nausea/pain
    Description: Audio-guided relaxation with safe place imagery. Purpose: reduce symptom intensity. Mechanism: engages top-down pain/nausea control. Benefits: quicker relief, less need for rescue meds.

19. Acceptance and commitment strategies
    Description: Learn to act by values even with symptoms. Purpose: sustain meaningful activity. Mechanism: psychological flexibility. Benefits: better quality of life.

20. Sleep hygiene coaching
    Description: Fixed wake time, screen limits, cool dark room, caffeine/alcohol avoidance. Purpose: improve sleep quality. Mechanism: strengthens circadian rhythm. Benefits: less daytime fatigue.

21. Nutrition education for cirrhosis/HCC
    Description: Small frequent meals, adequate protein (often 1.0–1.5 g/kg/day if approved), low sodium if ascites. Purpose: maintain muscle and albumin. Mechanism: corrects catabolism and fluid retention. Benefits: better strength and fewer hospitalizations.

22. Medication literacy sessions
    Description: Know your drugs, schedule, red-flag side effects, and interactions (e.g., avoid NSAIDs with cirrhosis). Purpose: safer self-care. Mechanism: informed adherence. Benefits: fewer complications.

23. Caregiver skills training
    Description: Safe transfers, skin care, fall prevention, and when to call. Purpose: home safety. Mechanism: practical coaching. Benefits: fewer injuries, less burnout.

24. Financial/social work navigation
    Description: Help with insurance, transport, nutrition support, and transplant evaluation steps. Purpose: reduce stress barriers. Mechanism: resource linkage. Benefits: better continuity of care.

25. Advance care planning conversation
    Description: Talk early about goals, preferences, and who speaks for you if you cannot. Purpose: align care with values. Mechanism: clear directives. Benefits: fewer unwanted treatments, more control.

---

Drug treatments

1. Atezolizumab + Bevacizumab (immunotherapy + anti-VEGF)
   Class: PD-L1 inhibitor + VEGF inhibitor (IV). Typical dosage/time: Atezolizumab 1200 mg IV plus Bevacizumab 15 mg/kg IV every 3 weeks, if endoscopy shows low bleeding risk. Purpose: first-line systemic therapy for unresectable/metastatic HCC. Mechanism: frees immune attack on tumor (PD-L1 blockade) and starves tumor vessels (VEGF blockade). Side effects: fatigue, high blood pressure, bleeding/protein in urine risk, immune-related events (hepatitis, colitis, pneumonitis) that may need steroids.

2. Durvalumab + Tremelimumab (STRIDE regimen)
   Class: PD-L1 inhibitor + CTLA-4 inhibitor. Dose/time: Single “priming” dose Tremelimumab 300 mg IV once + Durvalumab 1500 mg IV every 4 weeks. Purpose: first-line option when anti-VEGF is unsuitable. Mechanism: dual checkpoint release to activate T-cells. Side effects: immune-related organ inflammation, fatigue, rash, diarrhea; close monitoring needed.

3. Durvalumab monotherapy
   Class: PD-L1 inhibitor. Dose: 1500 mg IV every 4 weeks. Purpose: for some patients who cannot receive combination therapy. Mechanism: restores anti-tumor immunity. Side effects: as above but generally fewer than dual blockade.

4. Sorafenib
   Class: Multi-kinase TKI (oral). Dose: 400 mg twice daily, with adjustments. Purpose: systemic therapy when immunotherapy not possible. Mechanism: blocks RAF, VEGFR, PDGFR pathways. Side effects: hand-foot skin reaction, diarrhea, hypertension, fatigue, low appetite.

5. Lenvatinib
   Class: Multi-kinase TKI. Dose: 8 mg daily (<60 kg) or 12 mg daily (≥60 kg). Purpose: first-line alternative to sorafenib for unresectable HCC. Mechanism: inhibits VEGFR1–3, FGFR1–4, others. Side effects: hypertension, proteinuria, fatigue, appetite loss, hypothyroidism.

6. Regorafenib
   Class: TKI. Dose: 160 mg daily, 3 weeks on/1 week off (2nd-line after sorafenib if tolerated). Purpose: progression after sorafenib. Mechanism: multi-target anti-angiogenic. Side effects: hand-foot skin reaction, liver enzyme rise, fatigue, hypertension.

7. Cabozantinib
   Class: TKI. Dose: 60 mg daily (adjust as needed). Purpose: later line after sorafenib/lenvatinib. Mechanism: inhibits MET, AXL, VEGFR2. Side effects: diarrhea, fatigue, hand-foot syndrome, hypertension.

8. Ramucirumab
   Class: VEGFR-2 antibody (IV). Dose: 8 mg/kg every 2 weeks; used when AFP ≥400 ng/mL after sorafenib/lenvatinib. Purpose: targeted anti-angiogenic in a biomarker-selected group. Mechanism: blocks VEGF signaling at receptor. Side effects: hypertension, proteinuria, bleeding risk.

9. Nivolumab
   Class: PD-1 inhibitor (IV). Dose: 240 mg every 2 weeks or 480 mg every 4 weeks (some regions). Purpose: immunotherapy option in certain settings. Mechanism: reactivates exhausted T-cells. Side effects: immune-mediated hepatitis (watch LFTs), thyroiditis, rash, pneumonitis.

10. Pembrolizumab
    Class: PD-1 inhibitor. Dose: 200 mg every 3 weeks or 400 mg every 6 weeks. Purpose: post-TKI option in select patients. Mechanism: immune checkpoint blockade. Side effects: similar to nivolumab.

11. Transarterial chemoembolization (TACE) drugs (e.g., Doxorubicin/Cisplatin)
    Class: Locoregional chemotherapy delivered into tumor artery with embolic beads. Dose: procedural; not daily pills. Purpose: for liver-limited tumors not suitable for surgery. Mechanism: high local chemo + blood flow blockage starves tumor. Side effects: post-embolization syndrome (fever, pain), transient liver enzyme rise; rare liver failure.

12. Radioembolization (Y-90 microspheres)
    Class: Locoregional internal radiation via artery. Dose: procedural; personalized dosimetry. Purpose: treat liver-confined tumors, portal vein invasion cases. Mechanism: emits beta radiation inside tumor microvasculature. Side effects: fatigue, mild abdominal pain; rare radiation hepatitis.

13. Antivirals for HBV: Tenofovir or Entecavir
    Class: Nucleos(t)ide analogs (oral). Dose: Tenofovir 300 mg daily; Entecavir 0.5 mg daily (typical). Purpose: control hepatitis B to protect liver during cancer therapy and reduce decompensation. Mechanism: suppresses HBV replication. Side effects: kidney effects (tenofovir), headache, nausea—monitor labs.

14. Antivirals for HCV (e.g., Sofosbuvir/Velpatasvir)
    Class: Direct-acting antivirals. Dose: fixed combination once daily for 12 weeks (typical). Purpose: cure hepatitis C, improve liver function reserve for treatment options. Mechanism: blocks viral replication enzymes. Side effects: usually mild—fatigue, headache.

15. Hepatic encephalopathy control: Lactulose ± Rifaximin
    Class: Osmotic laxative + non-absorbed antibiotic. Dose: Lactulose titrated to 2–3 soft stools/day; Rifaximin 550 mg twice daily. Purpose: reduce confusion from ammonia in advanced liver disease. Mechanism: lowers ammonia absorption/production. Side effects: bloating/diarrhea (lactulose), rare GI upset (rifaximin).

---

Dietary molecular supplements

These are adjuncts. None cures HCC. Always ask your doctors—some herbs interact with TKIs or raise bleeding risk.

1. Branched-chain amino acids (BCAA)
   Dose: Often 4–12 g/day in divided doses as a medical food if advised. Function/mechanism: provide fuel for muscles and may support protein balance in cirrhosis; may reduce encephalopathy risk. Note: coordinate with dietitian.

2. Vitamin D
   Dose: Individualized (often 800–2000 IU/day), correct deficiency. Mechanism: supports bone, muscle, and immune signaling. Function: better fall prevention and general health; monitor levels to avoid excess.

3. Omega-3 fatty acids (EPA/DHA)
   Dose: 1–2 g/day of combined EPA/DHA (enteric-coated). Mechanism: anti-inflammatory lipid mediators. Function: may help appetite, weight stabilization, and triglycerides.

4. Thiamine (Vitamin B1)
   Dose: Replace deficiency (e.g., 50–100 mg/day) if poor intake or alcohol-related disease. Mechanism: supports energy metabolism. Function: reduces deficiency-related fatigue/neurologic issues.

5. Zinc
   Dose: 25–50 mg elemental zinc/day short term if deficient. Mechanism: cofactor in ammonia metabolism. Function: may support encephalopathy management; watch copper balance and stomach upset.

6. Selenium (only if deficient)
   Dose: 50–100 mcg/day if low; avoid high doses. Mechanism: antioxidant selenoproteins. Function: general oxidative stress control.

7. Probiotics (specific strains)
   Dose: As labeled for chosen product. Mechanism: modulates gut flora and ammonia-producing bacteria. Function: can complement encephalopathy strategies; check with team.

8. Protein powders (whey/pea)
   Dose: To reach daily protein goal safely. Mechanism: provides essential amino acids. Function: preserves lean mass; choose low-sodium options.

9. Turmeric/Curcumin (caution with TKIs/bleeding)
   Dose: Only if approved; quality-controlled standardized extract. Mechanism: anti-inflammatory pathways. Function: symptom support; interactions possible—get pharmacist clearance.

10. Coffee (dietary, not a pill)
    Dose: 1–3 cups/day if your doctor agrees and no reflux/heart issues. Mechanism: chlorogenic acids; observational links to liver protection. Function: may support liver health; avoid late-day intake.

---

Immunity-booster / regenerative / stem-cell” therapies

There are no approved stem-cell drugs that cure HCC. The options below are research-stage or supportive; they must only be given in clinical trials or when your oncology team recommends them.

1. Adoptive NK cell therapy (investigational)
   Dose: Trial-specific IV infusions. Function/mechanism: lab-expanded natural killer cells target tumor cells via activating receptors; may work with antibodies.

2. CAR-T cells targeting GPC3 (investigational)
   Dose: Trial protocols after lymphodepletion. Mechanism: engineered T-cells recognize GPC3 on HCC cells and kill them. Function: potential for deep responses; risks include cytokine release.

3. Dendritic cell vaccines (investigational)
   Dose: Series of injections with tumor antigens. Mechanism: primes T-cells to recognize HCC antigens. Function: may prolong immune surveillance; evidence still evolving.

4. Cytokine-induced killer (CIK) cells (investigational)
   Dose: Multiple IV infusions. Mechanism: mixed T/NK-like cells with non-MHC-restricted killing. Function: has been studied as adjuvant after resection/ablation.

5. Oncolytic viruses (e.g., Pexa-Vec; programs evolved/varied)
   Dose: Trial-based. Mechanism: viruses infect and lyse tumor cells, also stimulate immunity. Function: experimental; availability limited.

6. Hematologic growth factors (e.g., Pegfilgrastim) when indicated
   Dose: 6 mg SC once per chemo cycle if risk of neutropenia (per oncology). Mechanism: boosts white cells to prevent infection during systemic therapy. Function: protects treatment intensity; not an anti-cancer drug.

---

Procedures and surgeries

1. Liver resection (partial hepatectomy)
   Procedure: Surgical removal of the tumor with a margin if enough healthy liver remains and no major portal hypertension. Why: can be curative for a single lesion in good liver function.

2. Liver transplantation
   Procedure: Replace the diseased liver with a donor liver (living or deceased) if you meet criteria (such as Milan criteria). Why: removes both tumor and cirrhotic liver; offers best long-term cure in eligible patients.

3. Thermal ablation (Radiofrequency or Microwave)
   Procedure: Needle probes heat and destroy small tumors (usually ≤3 cm). Why: curative intent for small, localized lesions when surgery isn’t possible.

4. Transarterial chemoembolization (TACE)
   Procedure: Catheter delivers chemo and tiny particles to block tumor blood flow. Why: controls growth for liver-limited disease not fit for surgery/ablation.

5. Y-90 radioembolization
   Procedure: Catheter places radioactive microspheres into tumor arteries. Why: treats larger or portal-vein-involved tumors with focused internal radiation.

---

Prevention strategies

1. Get vaccinated for hepatitis B.

2. Treat chronic hepatitis B or C early with proper antivirals.

3. Avoid aflatoxin (store grains/nuts dry; discard moldy food).

4. Do not drink alcohol or keep intake very low if your doctor allows any.

5. Maintain a healthy weight and control diabetes to prevent fatty liver.

6. Do not smoke; avoid secondhand smoke.

7. Use medicines safely—avoid unnecessary NSAIDs and high-dose acetaminophen in liver disease; always ask doctors first.

8. Practice blood and needle safety; avoid sharing needles; use sterile equipment.

9. Occupational protection if exposed to chemicals; follow safety rules.

10. Regular ultrasound/AFP screening if you are high-risk (for example, hepatitis B/C or cirrhosis), usually every 6 months.

---

When to see doctors urgently

• New or worsening right-upper belly pain or swelling.

• Yellow eyes/skin, very dark urine, or very pale stools.

• Vomiting blood or black tarry stools.

• Sudden confusion, sleepiness, or personality change (possible encephalopathy).

• Rapid weight loss, persistent vomiting, no appetite for days.

• Fever, chills, or signs of infection during treatment.

• Severe fatigue that stops daily activity.

• New swelling in legs or belly, or shortness of breath.

If you’re on immunotherapy, call at once for any new diarrhea, cough/short breath, severe rash, or yellowing, because these can be immune side effects that need quick steroids.

---

What to eat and what to avoid

Eat:

• Small, frequent meals (every 3–4 hours) to limit muscle breakdown.

• Adequate protein (often 1.0–1.5 g/kg/day if your clinician approves), including fish, eggs, lean meats, tofu, dairy, or legumes.

• Complex carbs and healthy fats (whole grains, olive oil, nuts if safe).

• Low-sodium choices if you have ascites or swelling (aim <2 g/day).

• Plenty of safe, cooked vegetables and fruits (wash well; avoid raw if neutropenic).

• Clean water; consider 1–3 cups coffee/day if your clinician agrees.

Avoid or limit:

• Alcohol (strongly avoid).

• Very salty foods (pickles, instant noodles, chips, canned soups).

• Raw or undercooked shellfish (vibrio risk) and high-risk street foods.

• Excess herbal supplements without approval (interactions/bleeding).

• Large single heavy meals late at night (worsens reflux/sleep).

A registered dietitian with liver-cancer experience can tailor calories, protein, and sodium to you.

---

Frequently asked questions

1. Is hepatoma the same as HCC?
   Yes—hepatoma is an older name. The precise term is hepatocellular carcinoma (HCC).

2. Can HCC be cured?
   Yes, in selected people by resection, ablation, or transplantation. When cure isn’t possible, modern treatments can control the disease and improve survival.

3. How is treatment chosen?
   Doctors consider tumor size/number, blood vessel invasion, liver function (Child-Pugh), performance status, and patient goals—often using BCLC staging.

4. What is AFP?
   Alpha-fetoprotein is a blood marker sometimes high in HCC. It helps with monitoring, but some tumors make little AFP.

5. Why do I need an endoscopy before Bevacizumab?
   To check for esophageal varices that could bleed; they may be treated first to reduce risk.

6. If I have hepatitis B/C, is cancer contagious?
   HCC is not contagious. Hepatitis viruses can spread; vaccinate contacts for HBV and follow safety steps.

7. Can I exercise during treatment?
   Yes, with guidance. Light aerobic and resistance activity reduces fatigue and preserves muscle.

8. Should I avoid all painkillers?
   Avoid NSAIDs in cirrhosis unless your doctor approves. Acetaminophen can be used at lower safe doses per doctor advice. Always ask first.

9. Do immunotherapy drugs affect the liver?
   They can cause immune hepatitis. Teams monitor labs; report yellowing, dark urine, or right-upper pain promptly.

10. What if I am losing weight fast?
    Ask for dietitian support, BCAA options, and appetite strategies. Sometimes medicines help appetite; early action matters.

11. Does TACE or Y-90 stop me from future transplant?
    Not always. They’re often used as bridging therapies while on a transplant list, depending on your center’s policy.

12. How often is follow-up imaging?
    Commonly every 2–3 months during active therapy, then spaced out if stable—your team will set the schedule.

13. Can I take herbs like milk thistle?
    Only with oncology/hepatology approval. Some herbs interact with TKIs or raise bleeding risk.

14. What symptoms mean go to the ER now?
    Vomiting blood, black stools, severe confusion, high fever, severe short breath, sudden intense pain, or fast belly swelling.

15. How do I support my liver day to day?
    Do not drink alcohol, keep vaccines and antivirals up to date, eat small protein-adequate meals, stay active, keep sodium low if ascites, and go to all appointments.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 09, 2025.